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Abstract
Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late
stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to
Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening
on transmission. Here, we outline a method to estimate these parameters.
Methods: We first model the duration of stage 1 through survival analysis of untreated serological
suspects detected during Médecins Sans Frontières interventions in Uganda and Sudan. We then
deduce the duration of stage 2 based on the stage 1 to stage 2 ratio observed during active case
detection in villages within the same sites.
Results: Survival in stage 1 appears to decay exponentially (daily rate = 0.0019; mean stage 1
duration = 526 days [95%CI 357 to 833]), possibly explaining past reports of abnormally long
duration. Assuming epidemiological equilibrium, we estimate a similar duration of stage 2 (500 days
[95%CI 345 to 769]), for a total of nearly three years in the absence of treatment.
Conclusion:  Robust estimates of these basic epidemiological parameters are essential to
formulating a quantitative understanding of sleeping sickness dynamics, and will facilitate the
evaluation of different possible control strategies.
Background
Human African trypanosomiasis (sleeping sickness, HAT)
has historically been a predominant parasitic infection in
Africa, causing many millions of deaths in the late 1800s
through early 1900s, and has re-emerged in historical foci
after breakdown of control programmes [1]. Two forms of
HAT are recognised, due respectively to Trypanosoma brucei
gambiense (a mainly human disease found mainly in west-
ern and central Africa) and Trypanosoma brucei rhodesiense
(a zoonosis observed in eastern and southern Africa) [2].
Gambiense HAT has an insidious onset and progresses
over years, while rhodesiense HAT is fulminant, causing
death within a few months of infection [3]. In recent
years, 10 000–15 000 HAT cases (mostly gambiense) are
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reported annually [4], but this is likely an underestimate
of the true burden.
Fundamental aspects of the pathogenesis, clinical profile
and epidemiology of HAT remain poorly understood.
Infecting trypanosomes first colonise the haemo-lym-
phatic system, evading specific immunity through anti-
genic variation, but causing only mild and intermittent
symptoms – this is known as stage 1 (early or haemo-lym-
phatic stage). Eventually, parasites cross the blood-brain
barrier and cause severe neurological consequences, sys-
temic deterioration and, ultimately, death [5]. The period
after blood-brain barrier penetration is called stage 2 (late
or meningo-encephalitic stage).
The durations of both disease stages in gambiense HAT,
key parameters in the determination of the reproductive
ratio of HAT, are not well quantified, and understood
only on the basis of informal analysis or anecdote. Both
stage 1 and 2 are believed to last from months to years in
gambiense disease. However, atypically fast or slow pro-
gressions are reported and gambiense HAT, just like
rhodesiense, seems to exhibit a wide range of virulence,
often following geographical patterns [3,6,7].
In a separate paper (Checchi et al., submitted), we review
available evidence on the natural evolution of untreated
gambiense HAT, and consider the possible phenomenon
of trypano-tolerance, including instances where patients
might spontaneously clear their infections or become
chronic, asymptomatic carriers. We find that most infec-
tions are likely to be pathogenic and fatal if untreated, but
that chronic carriage cannot be ruled out based on availa-
ble evidence, and would, even if occurring at low frequen-
cies, play a crucial role in maintaining transmission even
in HAT foci where intensive case detection campaigns are
carried out. Trypano-tolerance is a well-described phe-
nomenon in cattle and other animal species [8], and has
been postulated by some as an explanation for the myste-
rious persistence of various historical HAT foci [6,9].
In the present paper, we focus on pathogenic T.b.gambi-
ense cases only, which probably constitute the majority of
infections, and estimate indirectly the duration of both
stage 1 and stage 2 from time of infection to death, in the
absence of treatment, based on observations of untreated
serological suspects, and the prevalence of the two stages
in defined populations. Rigorous and robust estimation
of these parameters is crucial to enable quantitative evalu-
ation of the potential of interventions to reduce transmis-
sion by minimising the period of human infectiousness to
flies [10]. Estimates for T.b.rhodesiense have been derived
elsewhere [11,12] by analysing patient-reported time
from symptom onset to stage 2 presentation or death.
Methods
Overall study design
The progression of HAT infection from stage 1 to stage 2
and from stage 2 to death or any other outcome, in the
absence of any treatment, can be modelled simply (Figure
1). Provided that model parameters specifying the pro-
gression rates from stage 1 (r1) and stage 2 (r2) can be esti-
mated, the mean and median durations of both stages,
and their confidence intervals, can easily be calculated.
Furthermore, if the numbers of stage 1 and stage 2 cases
are at steady state (equilibrium), the ratio of stage 1 to
stage 2 prevalence (S1/S2) will also be constant over time.
Assuming equilibrium, S1/S2  must be directly propor-
tional to the relative durations of stage 1 and stage 2; thus,
if one of the two durations is known, the other can be
deduced.
The challenge is to identify data from actual HAT foci that
can inform model parameters; and in particular, to esti-
mate r1 and/or r2 whilst maintaining the ethical obligation
to treat parasitologically confirmed infections immedi-
ately. Here, we use data from Médecins Sans Frontières
(MSF) HAT programmes to estimate (i) r1 from a survival
analysis of serological suspects kept under observation
without treatment, and (ii) S1 and S2 based on the output
of active screening sessions, in which communities are
tested exhaustively over the space of a few days, yielding
the point prevalence of each stage. We then deduce r2 from
the estimates of r1, S1 and S2.
Analysis was performed with Stata 9.0 software (Stata Cor-
poration, College Station, Texas, USA). Secondary analy-
sis of these operational data was approved by the Ethics
Committee of the London School of Hygiene and Tropical
Medicine.
Estimation of stage 1 to stage 2 progression rate (r1)
We pooled serological screening and individual patient
datasets from six MSF HAT control programmes (Moyo,
Uganda, 1986–1993; Adjumani, Uganda, 1991–1996;
Arua, Uganda, 1995–2002; Yumbe, Uganda, 2000–2002;
Kiri (Kajo Keji), southern Sudan, 2000–2005; Maridi,
southern Sudan, 1999–2005). Programmes and datasets
have been described previously [13,14]. Briefly, cases are
detected through a combination of passive (fixed-centre)
Simple model for the progression of untreated HAT Figure 1
Simple model for the progression of untreated HAT.
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and active (mass screening) case detection. Screening
relies on the serological Card Agglutination Test for
Trypanosomiasis (CATT, Institute of Tropical Medicine,
Antwerp, Belgium). Persons positive for the CATT in
whole blood go through a complex diagnostic algorithm
consisting of a repeat CATT test at progressively higher
dilutions, direct microscopy of aspirate from cervical
lymph nodes (if present), microscopical examination of
blood using one or more concentration techniques (the
Quantitative Buffy Coat, Woo, and/or mini-Anion
Exchange Column tests), and a lumbar puncture for stag-
ing purposes (microscopic evidence of trypanosomes or a
white blood cell [WBC] count >5/μL in cerebro-spinal
fluid [CSF] leads to stage 2 classification).
Frequently, individuals display a strong CATT reaction but
no parasitological evidence of HAT infection and are thus
classified as serological suspects. Because the CATT alone
is poorly predictive (specificity is around 95% but infec-
tion prevalence is usually <5%, giving positive predictive
values <50%) [15], treatment is withheld in such cases.
Serological suspects are asked to return for repeat testing
after three, six, nine, and twelve months, and are treated
immediately if found to have parasitologically confirmed
HAT, or released from further follow-up if the strong
CATT reaction disappears.
Our analysis focussed on stage 1 serological suspects,
defined as patients positive at a CATT dilution ≥1:4, but
with no parasitological evidence of HAT in any fluids, and
a CSF WBC count ≤5/μL. Among patients who were seen
at least once after initial screening, possible endpoints at
the last follow-up visit were defined as (i) non-case if the
CATT became negative or positive at a dilution <1:4, in
the absence of other parasitological evidence of HAT, (ii)
persistent suspect if positivity at CATT dilution ≥1:4
remained but other tests were still negative, (iii) con-
firmed stage 1 if blood or gland aspirate became positive
and CSF remained negative, or (iv) confirmed stage 2 if
parasites were observed in the CSF, if parasites were
observed only in blood or lymph fluid but CSF WBC
count exceeded 5/μL, or if the CSF WBC count exceeded
20/μL in the presence of a CATT dilution ≥1:4, irrespective
of other tests. Only patients who developed either stage 1
or 2 HAT during follow-up (endpoints (iii) and (iv)
above) were retained in this study for further survival
analysis. Among these, patients reaching endpoint (iv)
were considered to have progressed to stage 2, and those
with endpoint (iii) to have remained in stage 1 for the
duration of follow-up.
Maximum-likelihood estimation was used to fit paramet-
ric models to the observed survival data. While estimating
confidence intervals for model parameters, possible clus-
tering of survival probabilities within project sites was
adjusted for by considering each site as a cluster and tak-
ing into account within-cluster correlation of observa-
tions. So as to select an optimal model, different
hypotheses about the most closely fitting underlying dis-
tribution (exponential, Weibull, log-logistic, gamma, and
Gompertz) were evaluated using Wald tests if models
were nested (for example, the exponential distribution is
a particular case of the Weibull), or the Akaike Informa-
tion Criterion if they were not. Ordinarily, survival analy-
sis assumes that events occur when they are observed
(right-censoring). In our case, because follow-up visits
took place months apart, we decided against such an
assumption, and instead treated observations of stage 2
progression as interval-censored, i.e. considered simply
that progression had occurred within a time interval
defined by the visit when stage 2 was confirmed and the
previous visit (when it was known that the patient had not
yet progressed). This method implies likelihood expres-
sions that are somewhat different from the right censoring
case [16] and a user-defined Stata module for interval-cen-
sored survival analysis was applied [17]. So as to provide
some graphical assessment of the goodness of fit of the
parametric models, we compared fits of these models to a
non-parametric Kaplan-Meier curve of the survival data,
with Greenwood 95% confidence intervals, censoring
each progression event at the exact mid-point of the inter-
val between the two visits between which it was known to
have occurred (a close approximation to interval-censor-
ing).
The resulting model enables estimation of survival time in
stage 1 after detection. However, upon detection patients
will have already been infected for some time; the distri-
bution of these times since infection is unknown, and is
itself dependent on incidence trends in the pre-detection
period. If incidence is stable, this distribution will be uni-
form; if incidence is increasing, proportionately more will
have been infected recently. As illustrated in Figure 2, if
survival is dependent on time since infection, the
observed shape of the distribution of survival times after
detection will reflect both the distribution of times since
infection (itself a result of past incidence trends) and the
true distribution of survival in stage 1 (i.e. r1), as in scenar-
ios B1, B2, B3, C1, C2 and C3. If survival is in reality time-
independent (constant rate), both the true and observed
distributions will be exponential (scenarios A1, A2 and
A3), and will share the same parameter value, irrespective
of whether incidence is stable or not.
Estimation of S1 and S2
Data on active screening sessions were available from the
Adjumani, Arua, and Kiri programmes, and were used to
provide realistic values for S1 and S2 in situations unmodi-
fied by control. Screening sessions were retained for anal-
ysis only if they were the first to be conducted in theBMC Infectious Diseases 2008, 8:16 http://www.biomedcentral.com/1471-2334/8/16
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respective villages, reached a coverage (persons screened/
total population) ≥70% (a commonly used target in HAT
programmes), and yielded at least one case of HAT. The
mean and median S1 and S2, and their ratio, were calcu-
lated after weighting for village population size. We also
did sensitivity analysis to see whether passive case detec-
tion in the pre-screening period affected the S1 to S2 ratio.
Estimation of stage 2 removal rate (r2)
Assuming that no treatment is available, the prevalence of
cases in stage 2 at time t is given by the prevalence at the
previous time point (t - δt), plus new progressions from
stage 1, minus stage 2 patients removed, such that:
S2(t) = S2(t - δt) + S1(t - δt)r1 - S2(t - δt)r2 (1)
Assuming equilibrium conditions, S2(t) = S2(t - δt) = S2
and S1(t) = S1(t - δt) = S1. Thus, solving for r2 gives
rr
S
S
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1
2
=
⎛
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⎟ (2)
Expected shapes of the observed distribution of survival times after detection Figure 2
Expected shapes of the observed distribution of survival times after detection. Shaded cells A1-C3 show the 
expected distribution of survival times after detection, given different scenarios for the true distribution of stage 1 survival (A, 
B and C) and incidence in the pre-detection period (1, 2 and 3). P = proportion of cases remaining in stage 1; t = time; * = 
exponential function  , with mean stage 1 duration = 1/r1; ** = linear function P(t) = -r1t with fixed stage 1 duration 
= 1/r1.
1:  stable      
(equilibrium) 
2:  increasing 
(plausible) 
3:  decreasing 
(implausible) 
t after detection 
P
Expected shape of the 
true distribution of 
stage 1 survival after 
infection, given 
different scenarios: 
Approximate expected shape of the distribution of 
times since infection among patients detected, given 
different incidence () scenarios: 
P
P
A: time-
independent 
(constant rate) 
B: time-dependent 
(progression rate 
increases with 
time)  
C: time-
dependent 
(fixed duration 
of stage 1) 
* * *  * 
** 
A1 
B1 
C1 
A2 
B2 
C2 
A3 
B3 
C3 
t after detection  t after detection 
t after detection 
t after detection 
t after detection 
t after detection  t after detection 
t after detection 
t after infection 
t after infection 
t after infection 
t since infection  t since infection  t since infection 
PPP
P
P
P P
P P
PPP  
Observed shape of the distribution of stage 1 survival after 
detection, given combinations of the different scenarios: 
Pt e
rt ()
() =
− 1BMC Infectious Diseases 2008, 8:16 http://www.biomedcentral.com/1471-2334/8/16
Page 5 of 10
(page number not for citation purposes)
In an epidemiological scenario meeting the above
assumptions, the S1/S2 ratio is thus linearly proportional
to the relative duration of r2 and r1.
Results
Description of included and excluded patient cohorts
Out of 7742 patients listed as suspects in the six databases,
1079 were not eligible for the analysis: 385 (5.0%) had
laboratory findings compatible with confirmed stage 1 or
2 HAT and were in fact treated; 577 (7.5%) were stage 2
serological suspects; and 117 (1.5%) had an unclear stage
due to missing variables. This left 6663 (86.1%) patients
meeting stage 1 suspect criteria.
Baseline characteristics (Table 1) differed significantly
across sites (p < 0.001 for age; p < 0.001 for proportion
with zero WBC in CSF, with high levels in Maridi). Fol-
low-up rates were low everywhere (Table 1) with the
exception of Arua. Of the 6663 patients eligible, 2250
(33.8%) attended one follow-up visit, 580 (8.7%)
attended two, 232 (3.5%) three, 114 (1.7%) four, and two
(0.03%) five visits. Overall, 47.7% of suspects returned
for follow-up at least once. Attendance declined with time
(however, the low follow-up rates at months 9 and 12
partly reflect the fact that by then many patients had been
released from follow-up after becoming CATT negative).
Among patients seen once, person-time under observa-
tion was roughly comparable across sites.
Marked differences in patient endpoints were evident
across sites (Table 2). Most persons lost their strong CATT
reactivity during follow-up (non-cases), about a third
remained suspects, while parasitologically confirmed
HAT was noted in only a minority. Overall, 199 suspects
were confirmed as stage 1 during follow-up, and 99 pro-
gressed to confirmed stage 2 (Table 2), leaving 298 "true"
HAT cases among whom survival analysis was conducted.
The 298 patients retained differed systematically from the
remaining 6365 stage 1 suspects who were not confirmed
as stage 1 or 2 during follow-up, and thus excluded: they
were slightly younger (mean age 23.4 years versus 25.0
years, p = 0.029), a lower proportion had a WBC count of
zero in their CSF (109 [36.6%] versus 2801 [44.0%], p =
0.011), and a lower proportion were screened actively
(132 [44.3%] versus 3427 [53.8%], p = 0.001). Patients
followed up at least once also differed systematically from
those never seen again: more were female (1528/3178 or
48.1% versus 1565/3485 or 44.9%; p = 0.01); more had a
zero-WBC count in CSF (1438/3178 or 45.2% versus
1472/3485 or 42.2%; p = 0.01); and considerably more
were positive at a CATT dilution >1:4 (2165/2713 or
79.8% versus 1468/2305 or 63.7%; p < 0.001).
Stage 1 duration
After maximum likelihood estimation, a simple exponen-
tial model fit the data no worse (p > 0.20 for all compari-
sons among nested models) than any more complex
Table 1: Baseline characteristics and rates of follow-up of stage 1 serological suspects, by site
Adjumani, Uganda Arua, Uganda Moyo, Uganda Yumbe, Uganda Kiri, s. Sudan Maridi, s. Sudan Total
Number of patients 1140 2215 296 81 2201 730 6663
Baseline characteristics
Median age (IQR) 20 (12–32) 25 (14–35) 22 (12–36) 25 (13–40) 21 (13–32) 23 (15–35) 20 (12–33)
Number female (%) 595 (52.2) 1148 (51.8) 166 (56.1) 44 (54.3) 1231 (55.9) 386 (52.8) 3570 (53.6)
Number screened 
actively (%)
853 (74.8) 1362 (61.5) 239 (80.7) 14 (17.3) 926 (42.1) 165 (22.6) 3559 (53.4)
Number with zero WBC 
in CSF† (%)
607 (53.2) 1027 (46.4) 194 (65.5) 21 (25.9) 1052 (47.8) 9 (0.02) 2910 (43.7)
Follow-up rates
Not seen during follow-
up (%)
660 (57.9) 410 (18.5) 249 (84.1) 47 (58.0) 1502 (68.2) 617 (84.5) 3485 (52.3)
Seen at least once (%) 480 (42.1) 1805 (81.5) 47 (15.9) 34 (42.0) 699 (31.8) 113 (15.5) 3178 (47.7)
Seen at 3 months (%) 250 (21.9) 1180 (53.3) 23 (7.8) 25 (30.9) 412 (18.7) 63 (8.6) 1953 (29.3)
Seen at 6 months (%) 112 (9.8) 570 (25.7) 15 (2.1) 11 (13.6) 135 (6.1) 15 (2.0) 850 (12.8)
Seen at 9 months (%) 61 (5.3) 299 (13.5) 2 (0.7) 4 (4.9) 53 (2.4) 11 (1.5) 430 (6.5)
Seen at 12 months (%) 63 (5.5) 366 (16.5) 6 (2.0) 6 (7.4) 60 (2.7) 9 (1.2) 510 (7.6)
Median person-days of 
observation†† (IQR)
169 (98–277) 177 (97–328) 110 (97–201) 151 (98–271) 128 (96–209) 117 (93–198) 158 (97–281)
IQR = inter-quartile range; WBC = white blood cells; CSF = cerebrospinal fluid
†Note that all patients had ≤5 WBC/μL, as per stage 1 suspect definition. Presence of low WBC densities is generally not considered evidence of 
CSF infection, and the threshold of 5 cells/μL is also used in neurology.
††Among patients seen at least once.BMC Infectious Diseases 2008, 8:16 http://www.biomedcentral.com/1471-2334/8/16
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alternatives (Weibull, log-logistic, Gamma, and Gom-
pertz), as evidenced visually (Figure 3), and was thus
retained. Because distribution of survival times post detec-
tion is exponential, the overall function for survival in
stage 1 must also be exponential and have the same
parameter (Figure 2). The model thus yields the following
function for the proportion P of cases remaining in stage
1 up to time t:
where r1, the daily rate of progression to stage 2, is 0.0019
(95%CI 0.0012 to 0.0028). Accordingly, the mean dura-
tion of stage 1 is 1/r1, or 526 days (95%CI 357 to 833),
corresponding to about one and a half years. The median
duration is ln(2)/r1, or 364 days (95%CI 248 to 578).
The estimate of r1 is higher for patients detected though
passive screening at the HAT centre (0.0021, 95%CI
0.0012 to 0.0038) than for patients detected actively in
the community (0.0016, 95%CI 0.0013 to 0.0020). How-
ever, the difference is non-significant.
Stage 2 duration
Overall, 88 active screening sessions were eligible for anal-
ysis (Table 3). Infection prevalences were comparable in
Adjumani and Kiri, but considerably lower in Arua. Nev-
ertheless, the ratio of stage 1 and 2 prevalence was similar
across sites, and the overall average was close to unity
(1.04) considering the ratio of means, while a ratio of
medians yielded 1.25.
Using Equation 2, the stage 2 removal rate r2 was thus very
close to r1: 0.0020 per day (95%CI 0.0013 to 0.0029).
Accordingly, the mean duration of stage 2 is 1/0.0020 or
500 days (95%CI 345 to 769), and the mean total dura-
tion of stage 1 and 2 combined is 1026 days (95%CI 702
to 1602), or approximately 2 years and 10 months. Simi-
larly, the median stage 2 duration is 347 days (95%CI 239
to 533), giving a total median gambiense HAT duration of
711 days (95%CI 487 to 1111), or almost two years.
Sensitivity analysis to compare S1/S2 ratios according to
the pre-screening passive detection rate did not show sig-
nificant differences (p = 0.41 for detection rate <1 vs ≥1
per 1000 person-months, Kruskal-Wallis test).
Pt e
rt ()
() =
− 1 (3)
Fitted interval-censored stage 1 survival models Figure 3
Fitted interval-censored stage 1 survival models. For 
comparison purposes, the figure also superimposes a Kaplan-
Meier survival curve (with Greenwood 95% confidence inter-
vals) based on censoring progression events at the mid-point 
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Table 2: Endpoints during follow-up among stage 1 serological suspects who attended at least one control visit, by site
Adjumani, 
Uganda
Arua, 
Uganda
Moyo, 
Uganda
Yumbe, 
Uganda
Kiri, s. 
Sudan
Maridi, s. 
Sudan
Total
Not included in survival analysis
Dead (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.03)
Non-case (CATT reactivity waned) (%) 279 (58.1) 1198 
(66.4)
13 (27.7) 21 (61.8) 326 (46.6) 51 (45.1) 1888 (59.4)
Persistent suspect (%) 102 (21.3) 491 (27.2) 10 (21.3) 11 (32.4) 330 (47.2) 47 (41.6) 991 (31.2)
Included in survival analysis
Confirmed stage 1 HAT (%) 61 (12.7) 87 (4.8) 18 (38.3) 1 (2.9) 23 (3.3) 9 (8.0) 199 (6.3)
Progressed to stage 2 HAT (%) 38 (7.9) 29 (1.6) 6 (12.8) 1 (2.9) 19 (2.7) 6 (5.3) 99 (3.1)
Total 480 1805 47 34 699 113 3178
Median number of days between detection 
as stage 1 serological suspect and stage 2 
diagnosis (IQR)
179 
(99–319)
206 
(181–409)
213 
(103–417)
198 (single 
observation)
135 
(109–221)
64 (28–168) 189 (104–319)BMC Infectious Diseases 2008, 8:16 http://www.biomedcentral.com/1471-2334/8/16
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Discussion
Our estimate of the "natural" duration of gambiense HAT
(almost three years, evenly split between stage 1 and 2)
helps to refine commonly held views that both stages last
'months to years', and is broadly consistent with ranges
provided by experts: "several months to two years" for
stage 1 [7], and, for stage 2, "four months to one year" [7]
or "from one to three years" [3]. Fèvre et al. did survival
analysis on 96 gambiense patients reported in the histori-
cal literature, and estimated a median duration of three
years [18].
To our knowledge this is the first attempt to quantify the
duration of stage 1 and 2 specifically. Furthermore, the
distribution of stage 1 survival post detection has a clear
exponential shape. As shown in Figure 2, this observation
is most consistent with a constant, i.e. time-independent
rate of progression, irrespective of incidence trend before
detection (scenarios A1, A2 and A3), rendering our esti-
mates entirely robust in this respect. Distributions approx-
imating an exponential could also arise if incidence is
stable, and the progression rate increases with time (sce-
nario B1), or if incidence is decreasing (B3 or C3). How-
ever, the latter is implausible: in all sites, MSF intervened
because incidence was credibly reported to be increasing.
Our findings are least consistent with a time-dependent
progression rate in a scenario of increasing incidence,
which would yield strongly convex distributions (B2 and
C2).
The mathematical property of constant r1 is crucial to
interpreting observed variation in the virulence of HAT:
exponential distributions allow for a tail of unusually
long durations, reports of which abound in the literature
(Checchi et al., submitted). For example, using our esti-
mated survival function, 3% of cases would be expected to
remain in stage 1 for >5 years. Such cases should probably
no longer be considered extraordinary, but simply a result
of the intrinsic pattern of disease variability. The implica-
tion for control is that a small but important proportion
of cases can carry the infection for many years, and, if
undetected by active screening rounds, could maintain a
tiny but persistent infectious reservoir even when local
elimination appears all but achieved. Mop-up active
screening rounds, even years after transmission in a HAT
focus is considered to have been brought under control,
could thus play a vital role in reducing the risk of epi-
demic resurgence, something passive case detection might
by itself never achieve.
If stage 2 invariably progresses to death, as is widely
assumed, then r2 is the specific HAT death rate after stage
2 initiation, and 1/r2 is the life expectancy of stage 2. To
our knowledge only one other study has attempted to esti-
mate this parameter: Jusot et al. re-analysed observations
by Greggio on the survival of absconded HAT patients
diagnosed at a Belgian Congo hospital between 1907 and
1915 [19]. They showed an exponential decay of survival,
and estimated a daily death rate of 0.00235 (mean dura-
tion = 425 days), very close to our estimate.
Potential Biases
Our findings are subject to six main potential sources of
bias, which mainly affect the estimates of stage duration:
1. A systematic delay in ascertainment of stage 2 progres-
sion, leading to an underestimation of stage 1 duration,
could have occurred if patients had presented to the treat-
ment centre only when CNS involvement had become
symptomatic. Interval censoring removes part of this
potential bias by considering only the interval during
which the event occurred. Furthermore, only 29.3%
(1458/4971) of follow-up visits in our entire cohort of
6663 patients occurred >30 days earlier or later than
scheduled, suggesting that event ascertainment was
mainly driven by the follow-up schedule, not symptom
Table 3: Details of eligible active screening sessions and stage 1 and 2 prevalences
Adjumani Arua Kiri Total
Eligible screening s e s s i o n s  ( n ) 2 83 52 58 8
Years of intervention 1992–1994 1997–2000 2000–2004 -
Total population screened 17 550 78 268 16 231 112 049
Village population: median (IQR) 700 (417–1418) 2209 (1777–2558) 199 (115–260) 861 (287–2148)
Pre-screening passive detection rate: cases per 
1000 person-months, weighted median (range)
0.32 (0.00–6.33) 0.07 (0.00–2.24) 0.78 (0.00–30.46) 0.12 (0.00–30.46)
Stage 1 prevalence (S1): weighted mean % (range, 
median)
0.68 (0.00–5.67, 0.28) 0.14 (0.00–0.84, 0.07) 0.54 (0.00–2.31, 0.19) 0.24 (0.00–5.67, 0.10)
Stage 2 prevalence (S2): weighted mean % (range, 
median)
0.66 (0.00–6.67, 0.20) 0.12 (0.00–1.02, 0.07) 0.62 (0.00–6.48, 0.25) 0.23 (0.00–6.67, 0.08)
S1 to S2 ratio 1.03 1.17 0.87 1.04BMC Infectious Diseases 2008, 8:16 http://www.biomedcentral.com/1471-2334/8/16
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onset. There was a mean delay of 34 days between the
scheduled date of follow-up and the date when the visit
actually took place. This delay was greater when patients
were found to have progressed to stage 2 at the visit (56
days versus 34 days for all other visits; p = 001 for differ-
ence of means; p = 0.070 for difference of medians), but
this is a small difference considering HAT evolves over
many months. The distribution of visit timing with
respect to the scheduled date was similar whether or not
progression to stage 2 was detected at the visit (Figure 4).
2. About half of analysis-eligible patients were followed
up, each for an average of five months. At baseline, this
group had a higher prevalence of strong CATT reactivity
than defaulters, suggesting it harboured more true HAT
cases. This difference should have been eliminated by vir-
tue of including only confirmed stage 1 or 2 patients in
the survival analysis. Stage 1 duration may nonetheless
have been underestimated if patients progressing to stage
2 and thus feeling ill were more likely to present for fol-
low-up; however, this pattern may be unlikely given that
progression events occurred around scheduled visits. It is
also possible that patients progressing may have stayed
away from MSF HAT centres due to a perception that the
programme had failed to treat them: in this case, duration
would be overestimated.
3. Our analysis assumes that suspects have the same rate
of progression to stage 2 as 'typical' confirmed stage 1
patients. In fact, CATT serological suspects are a complex
population [20], probably composed of a mixture of false
parasitological negatives and false serological positives.
False negatives would be due to (i) testing during the pre-
patent phase (first 1–2 weeks after the tsetse bite); (ii)
low-virulence cases featuring a parasite density below the
detection threshold of microscopy; (iii) testing when par-
asite density is at its minimum, as part of its well-
described undulating pattern, and thus below the detec-
tion threshold; or (iv) laboratory error. False positives
would result from (i) CATT cross-reaction with other
trypanosome species (some of which are known to cause
transient and possibly even pathogenic infections), other
parasites such as leishmania and Plasmodium spp., or rheu-
matoid factors [21]; (ii) past HAT infection (antibodies
can survive for up to 3 years) [22]; or (iii) error in CATT
performance. So as to remove as many of the false posi-
tives as possible and isolate a population most likely to
comprise typical pathogenic infections, we restricted the
denominator at risk to suspect cases that were indeed true
HAT cases, as evidenced by stage 1 or 2 parasitological
confirmation during follow-up. Arguably, we could have
retained in the analysis individuals who remained sus-
pects until the end of follow-up, and the survival function
would have been markedly different, yielding a far longer
stage 1 duration (r1 = 0.00014, or about 20 years), which
Timing of actual follow-up visits with respect to the scheduled date Figure 4
Timing of actual follow-up visits with respect to the scheduled date. Data are provided for visits at which progression 
to stage 2 was detected (n = 99), as well as all other visits (n = 4774).
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does not seem plausible. However, the vast majority of
these cases have been shown in other studies to be false
positives by both parasitological and PCR techniques
[20,23-25]. Were suspects progressing more slowly than
other cases, the true stage 1 duration would be shorter
than our estimate: however, any difference is unlikely to
be great, since a much faster r1 than the one we measured
would yield durations of only a few months, consistent
with empirical observations of rhodesiense, but not gam-
biense HAT, for which one to three years are the norm
(Checchi et al, submitted).
4. Our estimate of r2 should be regarded as less robust and
potentially more biased than that of r1, since it relies on
an assumption of stable incidence, which is atypical in
HAT (indeed, past models of HAT transmission have sug-
gested unstable incidence and lack of equilibrium might
be an inherent feature of HAT dynamics) [19,26,27]. A ris-
ing incidence, which is more plausible, would skew the
S1/S2 ratio upwards, and result in an overestimation of r2,
i.e. underestimated stage 2 duration. This bias is probably
not large, since all foci in this analysis featured relatively
low prevalence (<2–3%), suggesting incidence may have
been rising slowly. However, our deduced stage 2 dura-
tion should be probably regarded as a lower-end estimate.
5. So as to assemble a sufficiently large cohort of patients,
we combined datasets from various HAT foci. We
assumed that this cohort would be representative of the
population of HAT patients in these foci. However, HAT
foci might differ in several ways. Particularly, incidence
trends might have been divergent (e.g. increasing in one
site and decreasing in another), affecting the stable inci-
dence assumption differently; and the profile of serologi-
cal suspects, including the prevalence of true HAT stage 1
cases (see point 3 above) might vary due to heterogeneity
in incidence, coverage and timeliness of case detection or
diagnostic sensitivity across sites: unequal representation
of the different foci in the overall cohort, due merely to
the duration and coverage of the respective treatment pro-
grammes and to incidence during the programme dura-
tions, would bias results towards the patterns in foci that
are over-represented in the cohort.
6. Estimates here apply to strains of T. gambiense present
in Sudan and Uganda. More or less virulent strains
encountered elsewhere might feature different progres-
sion and removal rates.
Conclusion
Our quantitative understanding of the dynamics of HAT is
poor relative to that of many other infectious diseases.
This is partly a consequence of imprecise knowledge of
the fundamental parameters that govern HAT disease
dynamics. Here we have estimated two of these key
parameters based on substantial datasets, providing esti-
mates of the true duration of untreated infections. These
parameter estimates are essential pre-requisites to the
development of formal approaches for the quantitative
evaluation of different strategies to control this neglected
disease. The duration of infection and thus infectiousness
is a fundamental determinant of HAT's reproductive ratio,
and present control strategies essentially work by reducing
r1 and r2: mathematical models will only offer reliable pre-
dictions of the impact of different screening strategies if
they incorporate realistic values for r1 and r2 [19]. Further-
more, the exponential property of stage 1 to stage 2 pro-
gression determines the distribution of asymptomatic
infection durations, and therefore the probability that
some long-duration cases will fall through the net of case
detection before they become symptomatic, and seed
renewed HAT outbreaks once control is relaxed. These
quantitative dynamic processes should inform any future
policies to control and possibly eliminate gambiense
HAT.
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